Fuso Pharmaceutical Industries (4538) Fundamentals 2026 — P/E 9.4x, Revenue Analysis | SniperIQ
Fuso Pharmaceutical Industries (4538) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥18.8B, trading at ¥2206.00 on the JPX. This SniperIQ fundamentals page covers Fuso Pharmaceutical Industries's valuation (P/E 9.4x, P/B 0.5x), profitability (net margin 3.2%), revenue (¥62.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fuso Pharmaceutical Industries's market cap?
Fuso Pharmaceutical Industries (4538) has a market capitalization of approximately ¥18.8B, trading at ¥2206.00 on the JPX. Market cap moves with the live share price.
What is Fuso Pharmaceutical Industries's P/E ratio?
Fuso Pharmaceutical Industries's trailing twelve-month P/E ratio is 9.4x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fuso Pharmaceutical Industries?
Fuso Pharmaceutical Industries runs a net profit margin of 3.2%, a gross margin of 25.7%, and an operating margin of 4.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fuso Pharmaceutical Industries generate?
Fuso Pharmaceutical Industries reported revenue of ¥62.3B for fiscal year 2025, with net income of ¥2.0B and earnings per share (EPS) of 235.52. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fuso Pharmaceutical Industries pay a dividend?
Fuso Pharmaceutical Industries offers a trailing dividend yield of about 4.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Fuso Pharmaceutical Industries financially healthy?
Fuso Pharmaceutical Industries carries a debt-to-equity ratio of 0.81x and a current ratio of 1.11x, with a market beta of 0.15. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fuso Pharmaceutical Industries a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fuso Pharmaceutical Industries (4538) the key facts are: market cap ¥18.8B, P/E 9.4x, revenue ¥62.3B, 52-week range 1990-2530. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Fuso Pharmaceutical Industries's full fundamentals live
Get Fuso Pharmaceutical Industries's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.